Your session is about to expire
← Back to Search
HER2/neu DNA Immunization for Breast Cancer
Study Summary
This trial will evaluate whether the injection of HER2/neu DNA is safe and stimulates an immune response in patients with breast cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2014 Phase 4 trial • 32 Patients • NCT01301729Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- It is expected that you may not live for more than 6 months.I have a history of heart disease, including heart attack, heart failure, or other heart conditions.You have a history of a weakened immune system or a condition where your immune system attacks your body.I am currently on antibiotics for an infection.I have not had any active cancers in the last 5 years, except for non-melanoma skin cancer.I have a tumor in my brain or spinal cord.I have received more than 600 mg/m2 of epirubicin.I am currently on hormonal therapy.I am currently taking or have taken Herceptin for my cancer.I haven't had major surgery or chemotherapy for 4 weeks, but I may be on hormonal therapy or trastuzumab.My blood tests show low white cells or platelets, or high kidney or liver markers.I have received more than 360 mg/m2 of doxorubicin.You are currently breastfeeding.My cancer can be measured, seen but not measured, or currently shows no signs.I am older than 18 years.I have received a breast cancer vaccine in the past.I can carry out normal activities with minimal symptoms.I am not on any medication that could interfere with treatment or vaccines.My cancer is HER2 positive based on specific tests.My breast cancer is advanced (Stage III or IV) and HER2 positive.I have stage IV breast cancer but currently show no signs of it getting worse.My breast cancer was stage III and I finished my treatment less than 3 years ago.
- Group 1: 1
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the aggregate number of participants for this experiment?
"Unfortunately, this medical study is no longer open for enrolment. It was first posted on the 1st of May 2006 and last updated on the 7th of October 2022. For those seeking alternative clinical studies to participate in, there are currently 2600 trials recruiting patients with breast cancer and 191 trails searching for people who might benefit from MAB HER 2 (HERCEPTIN) treatments."
What conditions is MAB HER 2 (HERCEPTIN) typically prescribed for?
"MAB HER 2 (HERCEPTIN) is a widely used intervention for breast cancer. Additionally, it may be beneficial in treating other illnesses such as reduced risk of recurrence and post-operative complications."
Has the Food and Drug Administration granted clearance to utilize MAB HER 2 (HERCEPTIN)?
"Due to the limited amount of evidence available on its efficacy and safety, MAB HER 2 (HERCEPTIN) was rated as a 1 with our team at Power."
Are there still opportunities to partake in this medical experiment?
"According to records from clinicaltrials.gov, this trial is not currently welcoming patients; however it was published on May 1st 2006 and updated on October 7th 2022. In the present moment, there are 2,791 other studies actively recruiting participants across the globe."
Share this study with friends
Copy Link
Messenger